title: The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
abstract: Peroxisome proliferator-activated receptor gamma (PPARγ) agonists have anticancer activity and influence cell differentiation. We examined the impact of the selective PPARγ agonist efatutazone on mammary cancer pathogenesis in a mouse model of BRCA1 mutation. Mice with conditional loss of full-length BRCA1 targeted to mammary epithelial cells in association with germline TP53 insufficiency were treated with efatutazone through the diet starting at age 4 months and were euthanized at age 12 months or when palpable tumor reached 1 cm(3). Although treatment did not reduce percentage of mice developing invasive cancer, it significantly reduced prevalence of noninvasive cancer and total number of cancers per mouse and increased prevalence of well-differentiated cancer subtypes not usually seen in this mouse model. Invasive cancers from controls were uniformly estrogen receptor α negative and undifferentiated, whereas well-differentiated estrogen receptor α-positive papillary invasive cancers appeared in efatutazone-treated mice. Expression levels of phosphorylated AKT and CDK6 were significantly reduced in the cancers developing in efatutazone-treated mice. Efatutazone treatment reduced rates of mammary epithelial cell proliferation and development of hyperplastic alveolar nodules and increased expression levels of the PPARγ target genes Adfp, Fabp4, and Pdhk4 in preneoplastic mammary tissue. Intervention efatutazone treatment in mice with BRCA1 deficiency altered mammary cancer development by promoting development of differentiated invasive cancer and reducing prevalence of noninvasive cancer and preneoplastic disease.
authors.affiliation: Department of Oncology, Georgetown University, Washington, District of Columbia 20057, USA.
authors.forename: Rebecca E
authors.initials: RE
authors.lastname: Nakles
authors.forename: Bhaskar V S
authors.initials: BV
authors.lastname: Kallakury
authors.forename: Priscilla A
authors.initials: PA
authors.lastname: Furth
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical / Q000379:methods; D047628:Estrogen Receptor alpha / Q000378:metabolism; D005260:Female; D019398:Genes, BRCA1; D016158:Genes, p53; D057895:Haploinsufficiency; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009154:Mutation; D009361:Neoplasm Invasiveness; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D011230:Precancerous Conditions / Q000517:prevention & control; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D045162:Thiazolidinediones / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D016588:Anticarcinogenic Agents; D047628:Estrogen Receptor alpha; D047495:PPAR gamma; D045162:Thiazolidinediones; D051057:Proto-Oncogene Proteins c-akt; C510342:efatutazone